Oruka Therapeutics, Inc. (HQ1.F)
Frankfurt · EUR · Healthcare · Biotechnology
€72.00 (+0.00%) as of
Key statistics
- Market cap
- 4.77B
- EPS (TTM)
- -1.75
- Dividend yield
- 0.00%
- 52-week range
- 22.20 – 97.00
- Beta
- -0.11
- Profit margin
- 0.00%
- Volume
- 156.00
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Menlo Park, CA, United States
- Employees
- 68
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.